|
gptkbp:instance_of
|
gptkb:Company
|
|
gptkbp:bfsLayer
|
4
|
|
gptkbp:bfsParent
|
gptkb:Ariad_Pharmaceuticals
|
|
gptkbp:acquired
|
$200 million funding
|
|
gptkbp:acquisition
|
Acquired by a larger pharmaceutical company
|
|
gptkbp:ceo
|
Gareth Lewis
|
|
gptkbp:clinical_trial
|
gptkb:Europe
gptkb:Asia
gptkb:United_States
ongoing
completed
suspended
Phase 2
Phase 3
terminated
Phase 1 trials
not yet recruiting
|
|
gptkbp:collaborates_with
|
gptkb:temple
|
|
gptkbp:develops
|
cell therapies
|
|
gptkbp:employees
|
200+
|
|
gptkbp:focus
|
gptkb:drug
|
|
gptkbp:founded
|
gptkb:2008
|
|
gptkbp:headquarters
|
gptkb:Oxford,_United_Kingdom
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
Adaptimmune Therapeutics
|
|
gptkbp:investment
|
gptkb:Sofinnova_Partners
gptkb:Bessemer_Venture_Partners
gptkb:Morningside_Ventures
gptkb:Canaan_Partners
gptkb:Orbi_Med_Advisors
|
|
gptkbp:language_of_instruction
|
gptkb:ADP-A2_M4
ADP-A2 M4 C D8
ADP-A2 M4-001
ADP-A2 M4-002
ADP-A2 M4-003
|
|
gptkbp:partnership
|
gptkb:Merck
gptkb:GSK
gptkb:Bristol-Myers_Squibb
gptkb:University_of_Pennsylvania
gptkb:Pfizer
gptkb:Novartis
|
|
gptkbp:research_areas
|
gptkb:physicist
immuno-oncology
cellular therapy
|
|
gptkbp:research_focus
|
solid tumors
hematological malignancies
|
|
gptkbp:revenue
|
$20 million (2020)
|
|
gptkbp:targets
|
gptkb:healthcare_organization
|
|
gptkbp:technology
|
SPEART-cell platform
|
|
gptkbp:traded_on
|
gptkb:NASDAQ
|
|
gptkbp:website
|
www.adaptimmune.com
|